img

Global Cystic Fibrosis (CF) Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Cystic Fibrosis (CF) Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Cystic fibrosis is a genetic disease that causes continuous lung infections and breathing problem over time. It is a progressive disease. The presence of imperfect gene causes a thick, sticky buildup of mucus in the lungs, intestine liver, pancreas, and other organs. The mucus in the lungs clogs airways and traps bacteria leading to infections that causes savior lung damage, and respiratory failure. The mucus prevents in the pancreas discharge the digestive enzymes that allow the body to break down food and absorb vital nutrients. This disease is caused by mutation in gene, cystic fibrosis trans membrane conductance regulator (CFTR) is a membrane protein in vertebrates, a protein required for regulating sweat, mucus and body secretions.
Due to the COVID-19 pandemic, the global Cystic Fibrosis (CF) Therapeutics market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Pancreatic enzyme supplements accounting for % of the Cystic Fibrosis (CF) Therapeutics global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Oral drugs segment is altered to an % CAGR throughout this forecast period.
The global key companies of Cystic Fibrosis (CF) Therapeutics include Vertex Pharmaceuticalsorporated, Gilead, AbbVie,, Novartis AG, F. Hoffmann-La Roche Ltd, Alaxia, Merck & Co., AIT (Advanced Inhalation Therapies) and ALLERGAN, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Cystic Fibrosis (CF) Therapeutics market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Cystic Fibrosis (CF) Therapeutics landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Cystic Fibrosis (CF) Therapeutics market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Cystic Fibrosis (CF) Therapeutics market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Cystic Fibrosis (CF) Therapeutics market. Readers of the report can become informed about current and future trends of the global Cystic Fibrosis (CF) Therapeutics market and how they will impact market growth during the forecast period.



By Company


Vertex Pharmaceuticalsorporated
Gilead
AbbVie,
Novartis AG
F. Hoffmann-La Roche Ltd
Alaxia
Merck & Co.
AIT (Advanced Inhalation Therapies)
ALLERGAN
AstraZeneca
Teva Pharmaceutical Industries Ltd
Alcresta
Segment by Type
Pancreatic enzyme supplements
Mucolytics
Bronchodilators
CFTR modulators

Segment by Application


Oral drugs
Inhaled drugs
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Cystic Fibrosis (CF) Therapeutics in global and regional level.
Chapter 3Detailed analysis of Cystic Fibrosis (CF) Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cystic Fibrosis (CF) Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Pancreatic enzyme supplements
1.2.3 Mucolytics
1.2.4 Bronchodilators
1.2.5 CFTR modulators
1.3 Market by Application
1.3.1 Global Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Oral drugs
1.3.3 Inhaled drugs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size (2018-2034)
2.2 Cystic Fibrosis (CF) Therapeutics Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2018-2024)
2.4 Global Cystic Fibrosis (CF) Therapeutics Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Cystic Fibrosis (CF) Therapeutics Countries Ranking by Market Size
3 Cystic Fibrosis (CF) Therapeutics Competitive by Company
3.1 Global Cystic Fibrosis (CF) Therapeutics Revenue by Players
3.1.1 Global Cystic Fibrosis (CF) Therapeutics Revenue by Players (2018-2024)
3.1.2 Global Cystic Fibrosis (CF) Therapeutics Market Share by Players (2018-2024)
3.2 Global Cystic Fibrosis (CF) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Cystic Fibrosis (CF) Therapeutics Revenue
3.4 Global Cystic Fibrosis (CF) Therapeutics Market Concentration Ratio
3.4.1 Global Cystic Fibrosis (CF) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cystic Fibrosis (CF) Therapeutics Revenue in 2022
3.5 Global Key Players of Cystic Fibrosis (CF) Therapeutics Head office and Area Served
3.6 Global Key Players of Cystic Fibrosis (CF) Therapeutics, Product and Application
3.7 Global Key Players of Cystic Fibrosis (CF) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Cystic Fibrosis (CF) Therapeutics Breakdown Data by Type
4.1 Global Cystic Fibrosis (CF) Therapeutics Historic Revenue by Type (2018-2024)
4.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Revenue by Type (2024-2034)
5 Global Cystic Fibrosis (CF) Therapeutics Breakdown Data by Application
5.1 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Application (2018-2024)
5.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024)
6.2 North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2034)
6.3 North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2034)
6.4 North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024)
7.2 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2034)
7.3 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2034)
7.4 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024)
8.2 Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2034)
8.3 Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2034)
8.4 Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024)
9.2 Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2034)
9.3 Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2034)
9.4 Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024)
10.2 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2034)
10.3 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2034)
10.4 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Vertex Pharmaceuticalsorporated
11.1.1 Vertex Pharmaceuticalsorporated Company Details
11.1.2 Vertex Pharmaceuticalsorporated Business Overview
11.1.3 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Products and Services
11.1.4 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.1.5 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.1.6 Vertex Pharmaceuticalsorporated Recent Development
11.2 Gilead
11.2.1 Gilead Company Details
11.2.2 Gilead Business Overview
11.2.3 Gilead Cystic Fibrosis (CF) Therapeutics Products and Services
11.2.4 Gilead Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.2.5 Gilead Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.2.6 Gilead Recent Development
11.3 AbbVie,
11.3.1 AbbVie, Company Details
11.3.2 AbbVie, Business Overview
11.3.3 AbbVie, Cystic Fibrosis (CF) Therapeutics Products and Services
11.3.4 AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.3.5 AbbVie, Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.3.6 AbbVie, Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Products and Services
11.4.4 Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.4.5 Novartis AG Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.4.6 Novartis AG Recent Development
11.5 F. Hoffmann-La Roche Ltd
11.5.1 F. Hoffmann-La Roche Ltd Company Details
11.5.2 F. Hoffmann-La Roche Ltd Business Overview
11.5.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Products and Services
11.5.4 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.5.5 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.5.6 F. Hoffmann-La Roche Ltd Recent Development
11.6 Alaxia
11.6.1 Alaxia Company Details
11.6.2 Alaxia Business Overview
11.6.3 Alaxia Cystic Fibrosis (CF) Therapeutics Products and Services
11.6.4 Alaxia Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.6.5 Alaxia Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.6.6 Alaxia Recent Development
11.7 Merck & Co.
11.7.1 Merck & Co. Company Details
11.7.2 Merck & Co. Business Overview
11.7.3 Merck & Co. Cystic Fibrosis (CF) Therapeutics Products and Services
11.7.4 Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.7.5 Merck & Co. Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.7.6 Merck & Co. Recent Development
11.8 AIT (Advanced Inhalation Therapies)
11.8.1 AIT (Advanced Inhalation Therapies) Company Details
11.8.2 AIT (Advanced Inhalation Therapies) Business Overview
11.8.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Products and Services
11.8.4 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.8.5 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.8.6 AIT (Advanced Inhalation Therapies) Recent Development
11.9 ALLERGAN
11.9.1 ALLERGAN Company Details
11.9.2 ALLERGAN Business Overview
11.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Products and Services
11.9.4 ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.9.5 ALLERGAN Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.9.6 ALLERGAN Recent Development
11.10 AstraZeneca
11.10.1 AstraZeneca Company Details
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Products and Services
11.10.4 AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.10.5 AstraZeneca Cystic Fibrosis (CF) Therapeutics SWOT Analysis
11.10.6 AstraZeneca Recent Development
11.11 Teva Pharmaceutical Industries Ltd
11.11.1 Teva Pharmaceutical Industries Ltd Company Details
11.11.2 Teva Pharmaceutical Industries Ltd Business Overview
11.11.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Products and Services
11.11.4 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.11.5 Teva Pharmaceutical Industries Ltd Recent Development
11.12 Alcresta
11.12.1 Alcresta Company Details
11.12.2 Alcresta Business Overview
11.12.3 Alcresta Cystic Fibrosis (CF) Therapeutics Products and Services
11.12.4 Alcresta Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
11.12.5 Alcresta Recent Development
12 Cystic Fibrosis (CF) Therapeutics Market Dynamics
12.1 Cystic Fibrosis (CF) Therapeutics Industry Trends
12.2 Cystic Fibrosis (CF) Therapeutics Market Drivers
12.3 Cystic Fibrosis (CF) Therapeutics Market Challenges
12.4 Cystic Fibrosis (CF) Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Pancreatic enzyme supplements
Table 3. Key Players of Mucolytics
Table 4. Key Players of Bronchodilators
Table 5. Key Players of CFTR modulators
Table 6. Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 7. Global Cystic Fibrosis (CF) Therapeutics Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 8. Global Cystic Fibrosis (CF) Therapeutics Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Cystic Fibrosis (CF) Therapeutics Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 10. Global Cystic Fibrosis (CF) Therapeutics Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 11. Global Cystic Fibrosis (CF) Therapeutics Revenue by Players (2018-2024) & (US$ Million)
Table 12. Global Cystic Fibrosis (CF) Therapeutics Market Share by Players (2018-2024)
Table 13. Global Top Cystic Fibrosis (CF) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cystic Fibrosis (CF) Therapeutics as of 2022)
Table 14. Ranking of Global Top Cystic Fibrosis (CF) Therapeutics Companies by Revenue (US$ Million) in 2022
Table 15. Global 5 Largest Players Market Share by Cystic Fibrosis (CF) Therapeutics Revenue (CR5 and HHI) & (2018-2024)
Table 16. Global Key Players of Cystic Fibrosis (CF) Therapeutics, Headquarters and Area Served
Table 17. Global Key Players of Cystic Fibrosis (CF) Therapeutics, Product and Application
Table 18. Global Key Players of Cystic Fibrosis (CF) Therapeutics, Date of Enter into This Industry
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Cystic Fibrosis (CF) Therapeutics Market Size by Type (2018-2024) & (US$ Million)
Table 21. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2018-2024)
Table 22. Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 23. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2024-2034)
Table 24. Global Cystic Fibrosis (CF) Therapeutics Market Size by Application (2018-2024) & (US$ Million)
Table 25. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2018-2024)
Table 26. Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 27. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2024-2034)
Table 28. North America Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 29. North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 30. North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 31. North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 32. North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 33. North America Cystic Fibrosis (CF) Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 34. North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 35. North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 36. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 37. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 38. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 39. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 40. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 41. Europe Cystic Fibrosis (CF) Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 42. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 43. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 44. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 45. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 46. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 47. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 48. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 49. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 50. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Region (2018-2024) & (US$ Million)
Table 51. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Region (2024-2034) & (US$ Million)
Table 52. Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 53. Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 54. Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 55. Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 56. Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 57. Latin America Cystic Fibrosis (CF) Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 58. Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 59. Latin America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 60. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 61. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 64. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 66. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 68. Vertex Pharmaceuticalsorporated Company Details
Table 69. Vertex Pharmaceuticalsorporated Business Overview
Table 70. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product and Services
Table 71. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 72. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 73. Vertex Pharmaceuticalsorporated Recent Development
Table 74. Gilead Company Details
Table 75. Gilead Business Overview
Table 76. Gilead Cystic Fibrosis (CF) Therapeutics Product and Services
Table 77. Gilead Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 78. Gilead Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 79. Gilead Recent Development
Table 80. AbbVie, Company Details
Table 81. AbbVie, Business Overview
Table 82. AbbVie, Cystic Fibrosis (CF) Therapeutics Product and Services
Table 83. AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 84. AbbVie, Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 85. AbbVie, Recent Development
Table 86. Novartis AG Company Details
Table 87. Novartis AG Business Overview
Table 88. Novartis AG Cystic Fibrosis (CF) Therapeutics Product and Services
Table 89. Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 90. Novartis AG Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 91. Novartis AG Recent Development
Table 92. F. Hoffmann-La Roche Ltd Company Details
Table 93. F. Hoffmann-La Roche Ltd Business Overview
Table 94. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product and Services
Table 95. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 96. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 97. F. Hoffmann-La Roche Ltd Recent Development
Table 98. Alaxia Company Details
Table 99. Alaxia Business Overview
Table 100. Alaxia Cystic Fibrosis (CF) Therapeutics Product and Services
Table 101. Alaxia Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 102. Alaxia Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 103. Alaxia Recent Development
Table 104. Merck & Co. Company Details
Table 105. Merck & Co. Business Overview
Table 106. Merck & Co. Cystic Fibrosis (CF) Therapeutics Product and Services
Table 107. Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 108. Merck & Co. Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 109. Merck & Co. Recent Development
Table 110. AIT (Advanced Inhalation Therapies) Company Details
Table 111. AIT (Advanced Inhalation Therapies) Business Overview
Table 112. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product and Services
Table 113. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 114. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 115. AIT (Advanced Inhalation Therapies) Recent Development
Table 116. ALLERGAN Company Details
Table 117. ALLERGAN Business Overview
Table 118. ALLERGAN Cystic Fibrosis (CF) Therapeutics Product and Services
Table 119. ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 120. ALLERGAN Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 121. ALLERGAN Recent Development
Table 122. AstraZeneca Company Details
Table 123. AstraZeneca Business Overview
Table 124. AstraZeneca Cystic Fibrosis (CF) Therapeutics Product and Services
Table 125. AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 126. AstraZeneca Cystic Fibrosis (CF) Therapeutics SWOT Analysis
Table 127. AstraZeneca Recent Development
Table 128. Teva Pharmaceutical Industries Ltd Company Details
Table 129. Teva Pharmaceutical Industries Ltd Business Overview
Table 130. Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product and Services
Table 131. Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 132. Teva Pharmaceutical Industries Ltd Recent Development
Table 133. Alcresta Company Details
Table 134. Alcresta Business Overview
Table 135. Alcresta Cystic Fibrosis (CF) Therapeutics Product and Services
Table 136. Alcresta Cystic Fibrosis (CF) Therapeutics Revenue in Cystic Fibrosis (CF) Therapeutics Business (2018-2024) & (US$ Million)
Table 137. Alcresta Recent Development
Table 138. Cystic Fibrosis (CF) Therapeutics Market Trends
Table 139. Cystic Fibrosis (CF) Therapeutics Market Drivers
Table 140. Cystic Fibrosis (CF) Therapeutics Market Challenges
Table 141. Cystic Fibrosis (CF) Therapeutics Market Restraints
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Cystic Fibrosis (CF) Therapeutics Product Picture
Figure 2. Global Cystic Fibrosis (CF) Therapeutics Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Cystic Fibrosis (CF) Therapeutics Market Share by Type: 2022 VS 2034
Figure 4. Pancreatic enzyme supplements Features
Figure 5. Mucolytics Features
Figure 6. Bronchodilators Features
Figure 7. CFTR modulators Features
Figure 8. Global Cystic Fibrosis (CF) Therapeutics Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 9. Global Cystic Fibrosis (CF) Therapeutics Market Share by Application: 2022 VS 2034
Figure 10. Oral drugs
Figure 11. Inhaled drugs
Figure 12. Cystic Fibrosis (CF) Therapeutics Report Years Considered
Figure 13. Global Cystic Fibrosis (CF) Therapeutics Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Cystic Fibrosis (CF) Therapeutics Market Size 2018-2034 (US$ Million)
Figure 15. Global Cystic Fibrosis (CF) Therapeutics Market Size Market Share by Region: 2022 VS 2034
Figure 16. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Region in 2018 VS 2022
Figure 17. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share Forecast by Region (2024-2034)
Figure 18. Global Top 10 Cystic Fibrosis (CF) Therapeutics Countries Ranking by Market Size (US$ Million) in 2022
Figure 19. Global Cystic Fibrosis (CF) Therapeutics Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 20. Global Cystic Fibrosis (CF) Therapeutics Market Share by Players in 2022
Figure 21. Global Top Cystic Fibrosis (CF) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cystic Fibrosis (CF) Therapeutics as of 2022)
Figure 22. The Top 10 and 5 Players Market Share by Cystic Fibrosis (CF) Therapeutics Revenue in 2022
Figure 23. North America Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Company in 2022
Figure 24. North America Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 25. North America Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 26. North America Cystic Fibrosis (CF) Therapeutics Revenue Share by Country (2018-2034)
Figure 27. U.S. Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 28. Canada Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 29. Europe Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Company in 2022
Figure 30. Europe Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 31. Europe Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 32. Europe Cystic Fibrosis (CF) Therapeutics Revenue Share by Country (2018-2034)
Figure 33. Germany Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 34. France Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 35. U.K. Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 36. Italy Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 37. Russia Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 38. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Company in 2022
Figure 39. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 40. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 41. Asia Pacific Cystic Fibrosis (CF) Therapeutics Revenue Share by Region (2018-2034)
Figure 42. China Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 43. Japan Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 44. South Korea Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 45. India Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 46. Australia Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 47. Taiwan Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 48. Indonesia Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 49. Thailand Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 50. Malaysia Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 51. Philippines Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 52. Vietnam Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 53. Latin America Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Company in 2022
Figure 54. Latin America Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 55. Latin America Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 56. Latin America Cystic Fibrosis (CF) Therapeutics Revenue Share by Country (2018-2034)
Figure 57. Mexico Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 58. Brazil Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 59. Argentina Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 60. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Company in 2022
Figure 61. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 62. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 63. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue Share by Country (2018-2034)
Figure 64. Turkey Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 65. Saudi Arabia Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 66. U.A.E Cystic Fibrosis (CF) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 67. Vertex Pharmaceuticalsorporated Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 68. Gilead Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 69. AbbVie, Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 70. Novartis AG Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 71. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 72. Alaxia Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 73. Merck & Co. Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 74. AIT (Advanced Inhalation Therapies) Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 75. ALLERGAN Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 76. AstraZeneca Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 77. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 78. Alcresta Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2018-2024)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed